The Filing Desk

Assembly Biosciences vs Viridian Therapeutics

Assembly Biosciences ASMB · Viridian Therapeutics VRDN · Pharmaceuticals

Assembly Biosciences reported revenue of $72 million in fiscal 2025, about the same as Viridian Therapeutics' $71 million in fiscal 2025. Assembly Biosciences' revenue grew 153.5% in its latest year, and Viridian Therapeutics' grew 23359.9%. Assembly Biosciences had an operating margin of -16.8%, against -512.9% at Viridian Therapeutics. Free cash flow was −$41 million at Assembly Biosciences and −$277 million at Viridian Therapeutics.

Side by side

Assembly BiosciencesViridian Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$72M$71M
Revenue growth153.5%23,359.9%
Revenue growth a year, last 5 years−1.8%130.0%
Gross margin——
Operating margin−16.8%−512.9%
Net margin−8.5%−483.6%
Free cash flow−$41M−$277M
Free cash flow margin−56.9%−390.8%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count86.7%—
Last close$22.50$31.44
P/E at the last close——
Insider trades, last 12 monthssold $14,687bought $20.0 million, sold $418,990
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Assembly BiosciencesViridian Therapeutics
Operating margin
Percent of revenue
Assembly BiosciencesViridian Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Assembly BiosciencesViridian Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Assembly Biosciences and Viridian Therapeutics pages.